S.M. Tolaney

Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study

Chiara Corti, S.M. Tolaney

We thank Dr. Wei and colleagues for their interest in our study on the impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage hormone receptor (HR)-positive/human epidermal growth factor receptor (HER2)-negative breast cancer (BC).1

us, it (code pays fourni par la source)

Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer

Simonetta Morganti, Ross J. Kusmick, Melissa E. Hughes, F. Brasó-Maristany et autres

BACKGROUND: Sacituzumab govitecan (SG) is an anti-trop2 antibody-drug conjugate (ADC) approved for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). However, data on effectiveness of SG and biomarkers remain limited. DNADX is a plasma-only multi-gene signature assay that identifies …

us, es, fr (code pays fourni par la source)

LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest

S. Loibl, Z. Jiang, Romualdo Barroso‐Sousa, Y.H. Park et autres

de, cn, br, kr, es, us, jp, tr, mx, tw, ca, it, nl, pl (code pays fourni par la source)

Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy

Ava Strahan, Qi Jin, Agepati S. Raghavendra, Danielle Brandes Zakon et autres

BACKGROUND: For patients diagnosed with triple-negative breast cancer (TNBC), residual disease (RD) after neoadjuvant chemotherapy (NAC) is associated with increased rates of recurrence and poor prognosis. Adjuvant therapy with capecitabine is considered standard management for TNBC-RD based on the CREATE-X study, although …

us (code pays fourni par la source)

Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib

Chiara Corti, Anthony R. Martin, Pramudya Kurnia, Jorge Gómez Tejeda Zañudo et autres

BACKGROUND: Two years of adjuvant abemaciclib with endocrine therapy (ET) is standard for high-risk estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, node-positive early-stage breast cancer. Relapse on adjuvant abemaciclib is poorly characterized. PATIENTS AND METHODS: Patients with recurrence on adjuvant …

it, us (code pays fourni par la source)

314P Outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC) according to BRCA and PD-L1 status

P. Tarantino, D. Lee, Julia Foldi, Pamela R. Soulos et autres

us, fr (code pays fourni par la source)

P439: ELEGANT: Elacestrant vs Standard ET in Women and Men With Node-positive, ER+, HER2- Early Breast Cancer (eBC) With High Risk of Recurrence – A Global, Multicenter, Randomized, Openlabel Phase 3 Study

A. Bardia, V. Kaklamani, J. O'Shaughnessy, Peter Schmid et autres

176P ERBB2 amplifications across sex, race, and cancer types

Marc Machaalani, R. El Hajj Chehade, A. Nassar, T. El Zarif et autres

us (code pays fourni par la source)

Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab

E.A. Mittendorf, Diego Malón, Guillermo Villacampa, A. Prat et autres

Importance: Biomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed. Objective: To determine if use of the HER2DX genomic assay (Reveal Genomics) in pretreatment baseline tissue samples of …

us (code pays fourni par la source)

Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer

H. Guo, E.P. Winer, LA Carey, W.T. Barry et autres

PURPOSE The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The primary analysis of the Adjuvant Paclitaxel and Trastuzumab trial demonstrated a 3-year disease-free survival (DFS) of …

us (code pays fourni par la source)

The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy

Y. Wu, R. Wesolowski, W. Osmani, Hans-Waldemar Brauer et autres

Purpose: Hormone receptor-positive/HER2-negative (HR+/HER2_) breast cancer is associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, and demonstrates poor responses to checkpoint inhibitor therapy. Evaluating the effect of standard chemotherapy on the immune microenvironment may suggest new opportunities for immunotherapy-based …

us (code pays fourni par la source)